This year's event will take place on Monday, April 15, 2024, and the UMass ALS Cellucci Fund is looking for marathon runners!
The UMass ALS Cellucci Fund is now accepting applications for charity runners who commit to raising at least $7,500 each for ALS research at UMass Chan Medical School. All applications must be completed and returned by Friday, Nov. 10, 2023, for consideration.
Using a short, synthetic chain of chemically modified nucleotides engineered in the RNA Therapeutics Institute at UMass Chan Medical School, Robert H. Brown Jr., DPhil, MD, Jonathan Watts, PhD, and colleagues have shown the ability to suppress mutant forms of the ALS (amyotrophic lateral sclerosis) gene known as C9ORF72 in a single-patient pilot study. C9ORF72 is the most common cause of familial ALS and familial frontotemporal dementia (FTD). The results, published in Nature Medicine, have the potential to catalyze research into treatments for ALS, FTD and other neurodegenerative diseases.
